Source: shutterstock.com/Champhei Long-term investors of Third Harmonic Bio (NASDAQ:THRD) are feeling some discomfort today, to put it mildly. This morning, THRD stock is losing the majority of its value because the company halted a clinical trial. Apparently, Third Harmonic did this due to safety-related issues. Third Harmonic Bio is a small clinical-stage biopharmaceutical company with…